Compare Cassava Sciences Inc (FLNA) vs iShares MSCI India ETF (INDA) Price & Performance

FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.

Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.

INDA, the iShares MSCI India ETF, trades at $48.71 with minimal daily movement (-0.04%). Technical indicators show a bearish trend with moving averages signaling caution, though RSI suggests potential oversold conditions. The ETF faces mixed sentiment as India's economy grows at 7.8% (CNBC, 2026-06-05) while navigating AI adoption challenges and geopolitical risks. Recent news highlights India's position as the world's fastest-growing large economy with ongoing comparisons to other emerging market ETFs.

The outlook for INDA balances strong economic growth fundamentals against near-term headwinds including foreign investor outflows and sector-specific pressures. Investment opportunity lies in India's structural growth story, while risks include Middle East tensions impacting inflation and currency stability. Analyst views remain divided with some seeing value in the ETF's sector composition and growth potential despite recent underperformance.